---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-011405"
form_type: "8-K"
ticker: "WINT"
cik: "0000946486"
company_name: "WINDTREE THERAPEUTICS INC /DE/"
filed_at: "2024-04-08T23:59:59+00:00"
generated_at: "2026-06-04T01:38:44.974946+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Windtree acquires Varian assets, issues $5.5M Series B Preferred and $1.5M convertible notes

## Summary
- 5,500 shares of Series B Convertible Preferred (stated value $5.5M) issued to Varian creditors as asset purchase consideration.
- Up to $2.3M in milestone payments for acquired cancer assets; Windtree may pay in cash or common stock.
- $1.5M senior convertible notes (10% interest, due Jan 2, 2025) at initial conversion price of $0.3603 per share.
- Notes and Preferred have 4.99% beneficial ownership cap and adjustable conversion floor of $0.0721.
- Registration rights agreement filed for resale of conversion shares; stockholder approval sought for issuances.

## SEC filing metadata
- accession: 0001437749-24-011405
- form_type: 8-K
- ticker: WINT
- cik: 0000946486
- company_name: WINDTREE THERAPEUTICS INC /DE/
- filed_at: 2024-04-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 5.03, 2.03, 3.02, 3.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/946486/000143774924011405/0001437749-24-011405-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/946486/000143774924011405/wint20240405_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-011405
- JSON: https://secwatch.observer/filing/0001437749-24-011405.json
- Plain text: https://secwatch.observer/filing/0001437749-24-011405.txt

## Key facts
- Debt Financings
  WINDTREE THERAPEUTICS INC /DE/ incurred senior notes of $1.5 million with the buyers named therein at 10.0% per annum maturing January 2, 2025.
  - Instrument: senior notes
  - Principal: $1.5 million
  - Counterparty: the buyers named therein
  - Rate: 10.0% per annum
  - Maturity: January 2, 2025
  - Event: incurrence
  source text: the Company agreed to sell senior convertible notes in an aggregate principal amount of $1.5 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/946486/000143774924011405/0001437749-24-011405-index.htm
- Governance Changes
  WINDTREE THERAPEUTICS INC /DE/: Filed Certificate of Designation establishing Series B Preferred Stock effective April 3, 2024 (effective 2024-04-03).
  - Change: charter amendment
  - Effective: 2024-04-03
  source text: Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. Pursuant to the Asset Purchase Agreement, the Company filed the Certificate of Designation with the Secretary of State of the State of Delaware on April 2, 2024 for the purpose of establishing and designating the Series B Preferred Stock. The Certificate of Designation became effective on April 3, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/946486/000143774924011405/0001437749-24-011405-index.htm
- Material Agreements
  WINDTREE THERAPEUTICS INC /DE/ entered into Asset Purchase Agreement with Varian Biopharmaceuticals, Inc. valued at up to $2,300,000 (effective 2024-04-02).
  - Action: entry
  - Agreement: asset purchase
  - Counterparty: Varian Biopharmaceuticals, Inc.
  - Value: up to $2,300,000
  - Effective: 2024-04-02
  source text: On April 2, 2024, Windtree Therapeutics, Inc., a Delaware corporation (the “Company”), entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”), by and between the Company and Varian Biopharmaceuticals, Inc., a Florida corporation (“Varian”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/946486/000143774924011405/0001437749-24-011405-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.